Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
Martin Tio1, Rajat Rai1, Ogochukwu M. Ezeoke2, Jennifer L. McQuade3, Lisa Zimmer4, Chloe Khoo5, John J. Park6,7, Lavinia Spain8, Samra Turajlic8,9, Luke Ardolino10, Desmond Yip11,12, Simone M. Goldinger13, Justine V. Cohen14, Michael Millward15, Victoria Atkinson16, Alisa Y. Kane17,18, Paolo A. Ascierto19, Claus Garbe20, Ralf Gutzmer21, Douglas B. Johnson22
1Melanoma Institute Australia, Sydney, Australia
2Memorial Sloan Kettering Cancer Center, New York, USA
3MD Anderson Cancer Center, Houston, USA
4University of Duisburg-Essen Hospital, Heidelberg, Germany
5Peter MacCallum Cancer Centre, Melbourne, Australia
6Crown Princess Mary Cancer Centre, Sydney, Australia
7Westmead Hospital, Sydney, Australia
8Skin and Renal Unit, The Royal Marsden NHS Foundation Trust, London, UK
9Francis Crick Institute, London, UK
10St Vincents Hospital, Sydney, Australia
11The Canberra Hospital, Canberra, Australia
12ANU Medical School, Australian National University, Canberra, Australia
13University Hospital Zurich, Zurich, Switzerland
14Massachusetts General Hospital, Boston, USA
15Sir Charles Gairdner Hospital, Perth, Australia
16Princess Alexandra Hospital, Brisbane, Australia
17Liverpool Hospital, Sydney, Australia
18Garvan Institute, Sydney, Australia
19Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy
20University of Tubingen, Tubingen, Germany
21Hannover Medical School, Hannover, Germany
22Vanderbilt Ingram Cancer Center, Nashville, USA
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
European Journal of Cancer
Tập 104
137-144
Thông tin tác giả